Butyrate‐Producing Bacteria in Intestinal Disease Therapy: Potential and Challenges

Butyrate-producing bacteria have emerged as keystone species whose metabolic activity orchestrates host-microbial homeostasis in the human gut. This review synthesizes current understanding of how these anaerobic Firmicutes, including Faecalibacterium prausnitzii, Roseburia spp., and Eubacterium rectale, function as key contributors to intestinal health through convergent mechanisms: serving as the primary energy source for colonocytes, enforcing mucosal hypoxia that excludes facultative pathogens, and modulating immunity via histone deacetylase inhibition and G-protein-coupled receptor signaling. We critically examine the translational trajectory of butyrogenic therapies across inflammatory bowel disease, colorectal cancer, and emerging applications in radiation injury, infection, and graft-versus-host disease. Despite compelling mechanistic rationale and consistent clinical associations linking butyrate-producer depletion with disease activity, therapeutic translation faces formidable bottlenecks: extreme oxygen sensitivity complicates manufacturing; cross-feeding networks necessitate ecological rather than monostrain approaches; and host context determines whether butyrate exerts protective or permissive effects. We evaluate cutting-edge strategies to overcome these barriers, including rationally designed consortia, precision prebiotics, phage-mediated niche engineering, synthetic biology approaches, and AI-guided personalization. By integrating mechanistic insight with translational pragmatism, this review outlines a path toward evidence-based butyrogenic therapies that may complement existing strategies for intestinal disease.